Recently a combination of an EGFR targeting antibody (Cetuximab)-functionalized gelatin nanoparticle (GAb) and covalently conjugated AXL siRNA containing nanoconstruct (GAbsiAXL) showed higher potential for intercellular internalization, improved the siRNA stability, and increased the expression of tumor suppressor P53 in drug-resistant NSCLC cells [294]. This evidence concerns the gene AXL and non-small cell lung carcinoma.